Stratos Genomics Revenue and Competitors
Estimated Revenue & Valuation
- Stratos Genomics's estimated annual revenue is currently $1.6M per year.
- Stratos Genomics's estimated revenue per employee is $155,000
Employee Data
- Stratos Genomics has 10 Employees.
- Stratos Genomics grew their employee count by 0% last year.
Stratos Genomics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Scientist | Reveal Email/Phone |
Stratos Genomics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.9M | 6 | 0% | N/A | N/A |
#2 | $0.9M | 6 | 0% | N/A | N/A |
#3 | $3.3M | 43 | 10% | $101M | N/A |
#4 | $5.7M | 37 | 12% | N/A | N/A |
#5 | $7M | 45 | 41% | N/A | N/A |
#6 | $1.7M | 22 | -8% | N/A | N/A |
#7 | $3.9M | 50 | 4% | $10.1M | N/A |
#8 | $1.9M | 12 | -73% | N/A | N/A |
#9 | $29.3M | 151 | -17% | $148M | N/A |
#10 | $2M | 13 | 86% | N/A | N/A |
What Is Stratos Genomics?
ULTRA-LOW-COST GENOME SEQUENCING Stratos Genomics' goal is to establish the next gold standard of DNA sequencing with its “Sequencing by Expansion™†(SBX) method. SBX is a simple, elegant, single-molecule detection process that circumvents the limitations of competing technologies, allowing accurate, ultra-low-cost whole-genome sequencing. With this advancement, SBX single-molecule sequencing technology will have a similar disruptive impact on the NGS market as PCR did for molecular diagnostics. SBX empowers you to do more, from targeted oncology panels and whole-genome sequencing to rapidly diagnosing infectious diseases.
keywords:N/AN/A
Total Funding
10
Number of Employees
$1.6M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Stratos Genomics News
... Future Genomics Technologies, Pacific Biosciences of California, NextOmics, BaseClear B.V., Stratos Genomics, Genome Transcriptome...
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.5M | 10 | -90% | N/A |
#2 | $0.9M | 10 | N/A | N/A |
#3 | $0.9M | 10 | N/A | N/A |
#4 | $0.9M | 10 | N/A | N/A |
#5 | $0.9M | 10 | N/A | N/A |
